Clinical Trials Sponsored by Sonexa Therapeutics, Inc

Total 3023 results

Aclaris Therapeutics, Inc.

Completed

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Rheumatoid Arthritis

United States
Repurposed Therapeutics, Inc.

Completed

Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion

Motion Sickness

United States
Stemline Therapeutics, Inc.

Completed

Tagraxofusp (SL-401) in Patients With CMML or MF

Myelofibrosis | Chronic Myelomonocytic Leukemia

United States, Canada
Axsome Therapeutics, Inc.

Completed

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

Major Depressive Disorder | Treatment Resistant Depression

United States
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

Amyotrophic Lateral Sclerosis | Frontotemporal Dementia

Spain, United States, Belgium, France, Germany
Talaris Therapeutics Inc.

Terminated

A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1)

Transplanted Organ Rejection

United States
Talaris Therapeutics Inc.

Withdrawn

A Safety and Efficacy Study of FCR001 Cell Therapy in Previously Transplanted Living Donor Kidney Recipients (FREEDOM-2)

Kidney Transplantation

United States
Aldeyra Therapeutics, Inc.

Completed

The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease

Dry Eye

United States
Ashvattha Therapeutics, Inc.

Terminated

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients (PRANA)

COVID-19

United States
Magenta Therapeutics, Inc.

Terminated

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

Acute Myeloid Leukemia | Myelodysplasia

United States
Zydus Therapeutics Inc.

Suspended

Evaluate the Safety and Efficacy of Saroglitazar Mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL

Dyslipidemias

United States
Sorrento Therapeutics, Inc.

Terminated

Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)

Covid19

United Kingdom
Karyopharm Therapeutics Inc

Completed

Selinexor Treatment of Refractory Myeloma (STORM)

Multiple Myeloma

United States, Belgium, Austria, France, Germany, Greece
Karyopharm Therapeutics Inc

Completed

Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies (SIGN)

Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma

Denmark, Belgium
Karyopharm Therapeutics Inc

Completed

Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer

Hematological Malignancies

United States, Denmark, Canada
Karyopharm Therapeutics Inc

Terminated

Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation (SIRRT)

Richter's Transformation

United States, Germany, United Kingdom, Spain, Poland
Karyopharm Therapeutics Inc

Withdrawn

Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients (SIER)

Myelodysplastic Syndrome
Sorrento Therapeutics, Inc.

Enrolling by invitation

Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy

Long-term Follow-up

United States
Karyopharm Therapeutics Inc

Withdrawn

Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19

Coronavirus Infection
Karyopharm Therapeutics Inc

Withdrawn

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients

Diabetic Foot Ulcers

New Zealand
Karyopharm Therapeutics Inc

Terminated

Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults

Healthy

Australia
Xalud Therapeutics, Inc.

Completed

Efficacy and Safety of XT-150 in Osteoarthritis of the Knee

Osteoarthritis, Knee

Australia, United States
Aldeyra Therapeutics, Inc.

Completed

A Double Masked, Placebo Controlled, Single Center, Randomized Clinical Trial to Assess the Safety and Efficacy of Subjects With Mild Asthma Induced by the Bronchial Allergen Challenge (BAC)

Atopic Asthma

Canada
Cidara Therapeutics Inc.

Completed

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis (ReSTORE)

Mycoses | Candidemia | Fungal Infection | Invasive Candidiases

United States, Israel, Spain, Korea, Republic of, Taiwan, Singapore, Thailand, Australia, China, Turkey, Belgium, Germany, France, Argentina, Bulgaria, Colombia, Greece, Italy
Cardiol Therapeutics Inc.

Terminated

Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors

Cardiovascular Diseases | COVID-19 | Cardiovascular Risk Factor

United States, Brazil, Mexico
Applied Therapeutics, Inc.

Active, not recruiting

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Diabetic Cardiomyopathies

United States, France, Spain, Australia, Canada, United Kingdom, Germany, Czechia, Hong Kong, Poland
Abeona Therapeutics, Inc

Completed

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Epidermolysis Bullosa | Recessive Dystrophic Epidermolysis Bullosa

United States
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Antios Therapeutics, Inc

Terminated

Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects

Chronic Hepatitis b

United States
Samus Therapeutics, Inc.

Terminated

Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States
Samus Therapeutics, Inc.

Withdrawn

Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS)
Lisata Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)

Critical Limb Ischemia | Thromboangiitis Obliterans | Buerger Disease | Atherosclerosis Obliterans

Japan
Kymera Therapeutics, Inc.

Completed

A Single and Multiple Ascending Dose Trial of KT-474 in Healthy Adult Volunteers and Patients With Atopic Dermatitis (AD) or Hidradenitis Suppurativa (HS)

Atopic Dermatitis | Healthy Volunteer | Hidradenitis Suppurativa

United States
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
Biosplice Therapeutics, Inc.

Active, not recruiting

A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors

Solid Tumor, Adult

United States
InteKrin Therapeutics, Inc.

Completed

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Axsome Therapeutics, Inc.

Completed

Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study (SHARP)

Obstructive Sleep Apnea | Excessive Daytime Sleepiness | Impaired Cognitive Function

Spain, United States, Canada, Netherlands, Italy, United Kingdom
Regulus Therapeutics Inc.

Completed

A Study of RGLS8429 in Healthy Volunteers

Healthy Volunteers

United States
Axsome Therapeutics, Inc.

Completed

A Trial of AXS-05 in Patients With Major Depressive Disorder (GEMINI)

Depression | Major Depressive Disorder

United States
Pipeline Therapeutics, Inc.

Completed

PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers

Multiple Sclerosis

United Kingdom
Protagonist Therapeutics, Inc.

Completed

Pharmacokinetics of PN-232 in Healthy Volunteers

Healthy Subjects

Australia
Gemini Therapeutics, Inc.

Terminated

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

Macular Degeneration | Retinal Degeneration | Geographic Atrophy | Dry Age-related Macular Degeneration | Retinal Disease

United States
LENZ Therapeutics, Inc

Completed

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

Presbyopia

United States
Ashvattha Therapeutics, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Australia
CymaBay Therapeutics, Inc.

Terminated

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

NASH - Nonalcoholic Steatohepatitis

United States
Jounce Therapeutics, Inc.

Completed

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (EMERGE)

Cancer

United States, Canada
Eureka Therapeutics Inc.

Terminated

Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma (ET-109)

Hepatocellular Carcinoma | Liver Neoplasm | Liver Cancer | Metastatic Liver Cancer

United States
Stemline Therapeutics, Inc.

Completed

Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer

Metastatic Breast Cancer

Netherlands, Belgium
Seres Therapeutics, Inc.

Terminated

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis (ECO-RESET)

Ulcerative Colitis

United States, Canada
NFlection Therapeutics, Inc.

Completed

NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Neurofibromatosis 1 | Cutaneous Neurofibroma

United States

Clinical Trials Sponsored by Sonexa Therapeutics, Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations